Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
CRG is a market pioneer and innovator in healthcare investing that focuses on intellectual property investments in FDA-approved biopharmaceutical assets through royalty bonds, structured debt, revenue interests, and traditional royalty monetizations. The company targets investments between $20 and $200 million and works directly with leading healthcare companies, research institutions, and inventors to provide customized financing structures to meet their unique needs. Its financings are an attractive alternative to costly equity financings and restrictive debt financings. CRG helps healthcare organizations fund pipeline development, make acquisitions, and expand into new markets—all with an adaptable source of capital. Capital Royalty strives to help biopharma companies access capital that has little to no dilution. While much of the capital that we invest allows our counterparties to fund innovative research and development products, our primary source of collateral is derived from commercialized products. As the only investment team with experience in structuring royalty bonds, structured debt, and traditional royalty monetizations, Capital Royalty is uniquely qualified to meet a broad range of financing needs for healthcare companies. CRG provides superior risk-adjusted returns to our investors by offering the most attractive financing alternatives to our business partners. Its investors include pension funds, insurance companies, family offices, university endowments, foundations, financial institutions, and other institutional investors.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2018 | Fast Pace Health | Private Equity Round | - |
2/2017 | BioDelivery Sciences | Post-IPO Debt | - |
5/2015 | Ceterix Orthopaedics | Debt Financing | 35M |
1/2016 | Realeve | Debt Financing | - |
7/2017 | Strongbridge Biopharma | Post-IPO Debt | 50M |
7/2017 | Strongbridge Biopharma | Post-IPO Equity | 3M |
3/2019 | Harmony Biosciences | Debt Financing | 200M |
3/2015 | TearLab | Post-IPO Debt | 35M |
9/2016 | Access TeleCare | Debt Financing | 45M |
5/2014 | AFT Pharmaceuticals | Debt Financing | 53M |
7/2022 | Calyxo | Series C | 32.7M |
1/2017 | EndoCeutics | Debt Financing | 85M |
12/2016 | T2 Biosystems | Post-IPO Debt | 50M |
11/2018 | HNI Healthcare | Private Equity Round | 65M |
2/2019 | EyePoint Pharmaceuticals | Debt Financing | 60M |
2/2018 | Dynavax Technologies | Post-IPO Debt | 175M |
4/2014 | NanoString Technologies | Post-IPO Debt | 45M |
7/2016 | US WorldMeds | Venture Round | - |
6/2016 | Iroko Pharmaceuticals | Debt Financing | 140M |
10/2013 | Exagen | Series D | 5M |
9/2015 | Avinger | Post-IPO Equity | 55M |
10/2015 | Silk Road Medical | Private Equity Round | 57M |
5/2019 | Aerin Medical | Debt Financing | 50M |
1/2015 | Imaging Advantage | Private Equity Round | 250M |
10/2014 | Blue Belt Technologies | Debt Financing | 44M |
6/2013 | Valeritas | Debt Financing | 100M |
6/2016 | Cardiome Pharma | Post-IPO Debt | 30M |
9/2017 | Synergy Pharmaceuticals | Post-IPO Debt | 300M |
6/2015 | ViewRay | Post-IPO Debt | 50M |
5/2017 | Viveve | Post-IPO Debt | 30M |
11/2013 | Exagen | Debt Financing | 25M |
6/2017 | Earlens | Debt Financing | 45M |
7/2014 | Exagen | Debt Financing | 4M |
5/2013 | Good Start Genetics | Debt Financing | 28M |
1/2019 | Mid-Atlantic Dental Partners | Venture Round | 70M |
1/2015 | Imaging Advantage | Debt Financing | - |
8/2020 | Treace Medical Concepts | Debt Financing | 50M |
12/2016 | Hicuity Health | Debt Financing | 2M |
5/2012 | Bioniche Pharma Group | Debt Financing | 20M |
1/2014 | Biodesix | Debt Financing | 20M |
7/2017 | Silk Road Medical | Series C | 0 |
9/2015 | GenomeDx Biosciences | Debt Financing | - |
6/2015 | Outset Medical | Debt Financing | 45M |
9/2013 | RainDance Technologies | Debt Financing | 35M |
6/2018 | EndoGastric Solutions | Series I | 0 |
10/2018 | Earlens | Series D | 0 |
12/2015 | EndoGastric Solutions | Venture Round | 0 |
1/2016 | Benvenue Medical | Debt Financing | 60M |
6/2017 | Earlens | Series C | 0 |
12/2014 | Nevro | Debt Financing | 50M |
5/2015 | Navidea Biopharmaceuticals | Post-IPO Debt | 60M |
12/2016 | Intrinsic Therapeutics | Venture Round | 17.9M |
5/2021 | NavaDerm | Debt Financing | 30M |
11/2016 | Omeros | Post-IPO Debt | 125M |
10/2014 | Astute Medical | Debt Financing | 40M |
12/2012 | Corium International | Convertible Note | 45M |
5/2016 | Valeritas | Venture Round | - |
11/2013 | Solta Medical | Post-IPO Equity | 40M |
2/2013 | TriVascular | Debt Financing | 96M |
1/2013 | Tandem Diabetes Care | Debt Financing | 80M |
7/2022 | Calyxo | Series C | 0 |
5/2021 | NavaDerm | Debt Financing | 0 |
8/2020 | Treace Medical Concepts | Debt Financing | 0 |
5/2019 | Aerin Medical | Debt Financing | 0 |
3/2019 | Harmony Biosciences | Debt Financing | 0 |
2/2019 | EyePoint Pharmaceuticals | Debt Financing | 0 |
1/2019 | Mid-Atlantic Dental Partners | Venture Round | 0 |
11/2018 | HNI Healthcare | Private Equity Round | 0 |
10/2018 | Earlens | Series D | 0 |
6/2018 | EndoGastric Solutions | Series I | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|